Published in Clin Cancer Res on February 13, 2014
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. N Engl J Med (2016) 2.54
Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy. Oncotarget (2016) 1.17
Large T and small T antigens of Merkel cell polyomavirus. Curr Opin Virol (2015) 0.93
Merkel cell polyomavirus: molecular insights into the most recently discovered human tumour virus. Cancers (Basel) (2014) 0.87
Large-scale detection of antigen-specific T cells using peptide-MHC-I multimers labeled with DNA barcodes. Nat Biotechnol (2016) 0.81
Broadening the repertoire of melanoma-associated T-cell epitopes. Cancer Immunol Immunother (2015) 0.79
Systemic Therapy for Merkel Cell Carcinoma: What's on the Horizon? Cancers (Basel) (2014) 0.77
Tumor-Infiltrating Merkel Cell Polyomavirus-Specific T Cells Are Diverse and Associated with Improved Patient Survival. Cancer Immunol Res (2017) 0.76
Major Histocompatibility Complex (MHC) Class I and MHC Class II Proteins: Conformational Plasticity in Antigen Presentation. Front Immunol (2017) 0.75
Reversal of epigenetic silencing of MHC class I chain-related protein A and B improves immune recognition of Merkel cell carcinoma. Sci Rep (2016) 0.75
Preclinical evaluation of NF-κB-triggered dendritic cells expressing the viral oncogenic driver of Merkel cell carcinoma for therapeutic vaccination. Ther Adv Med Oncol (2017) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08
Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science (2008) 16.60
SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics (1999) 14.15
Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol (2009) 5.33
T antigen mutations are a human tumor-specific signature for Merkel cell polyomavirus. Proc Natl Acad Sci U S A (2008) 4.74
Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features. J Am Acad Dermatol (2008) 4.69
Design and use of conditional MHC class I ligands. Nat Med (2006) 3.01
Merkel cell polyomavirus-infected Merkel cell carcinoma cells require expression of viral T antigens. J Virol (2010) 2.88
Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system. J Am Acad Dermatol (2010) 2.83
Accurate approximation method for prediction of class I MHC affinities for peptides of length 8, 10 and 11 using prediction tools trained on 9mers. Bioinformatics (2008) 2.69
Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers. Nat Methods (2009) 2.57
Transcriptome-wide studies of merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival. J Clin Oncol (2011) 2.52
Generation of peptide-MHC class I complexes through UV-mediated ligand exchange. Nat Protoc (2006) 2.47
Human Merkel cell polyomavirus small T antigen is an oncoprotein targeting the 4E-BP1 translation regulator. J Clin Invest (2011) 2.37
Antibodies to merkel cell polyomavirus T antigen oncoproteins reflect tumor burden in merkel cell carcinoma patients. Cancer Res (2010) 2.14
A cornucopia of human polyomaviruses. Nat Rev Microbiol (2013) 2.08
Quantitation of human seroresponsiveness to Merkel cell polyomavirus. PLoS Pathog (2009) 2.08
Recognition of influenza A matrix protein by HLA-A2-restricted cytotoxic T lymphocytes. Use of analogues to orientate the matrix peptide in the HLA-A2 binding site. J Exp Med (1988) 1.97
Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res (2012) 1.90
Conditional MHC class I ligands and peptide exchange technology for the human MHC gene products HLA-A1, -A3, -A11, and -B7. Proc Natl Acad Sci U S A (2008) 1.77
Parallel detection of antigen-specific T cell responses by combinatorial encoding of MHC multimers. Nat Protoc (2012) 1.76
Merkel cell carcinoma of the skin: pathological and molecular evidence for a causative role of MCV in oncogenesis. J Pathol (2009) 1.65
Improved detection suggests all Merkel cell carcinomas harbor Merkel polyomavirus. J Clin Invest (2012) 1.61
High levels of antibodies against merkel cell polyomavirus identify a subset of patients with merkel cell carcinoma with better clinical outcome. J Clin Oncol (2011) 1.53
Dissection of T-cell antigen specificity in human melanoma. Cancer Res (2012) 1.52
An intact retinoblastoma protein-binding site in Merkel cell polyomavirus large T antigen is required for promoting growth of Merkel cell carcinoma cells. Int J Cancer (2011) 1.49
Distinct merkel cell polyomavirus molecular features in tumour and non tumour specimens from patients with merkel cell carcinoma. PLoS Pathog (2010) 1.40
Merkel cell polyomavirus-specific CD8⁺ and CD4⁺ T-cell responses identified in Merkel cell carcinomas and blood. Clin Cancer Res (2011) 1.36
Serological evidence of Merkel cell polyomavirus primary infections in childhood. J Clin Virol (2010) 1.34
Systemic immune suppression predicts diminished Merkel cell carcinoma-specific survival independent of stage. J Invest Dermatol (2012) 1.30
Immune-suppressive properties of the tumor microenvironment. Cancer Immunol Immunother (2013) 1.27
Merkel cell polyomavirus: a newly discovered human virus with oncogenic potential. Virology (2013) 1.27
Merkel polyomavirus-specific T cells fluctuate with merkel cell carcinoma burden and express therapeutically targetable PD-1 and Tim-3 exhaustion markers. Clin Cancer Res (2013) 1.22
Genetic variability and integration of Merkel cell polyomavirus in Merkel cell carcinoma. Virology (2012) 1.16
Tumor-specific T cells in human Merkel cell carcinomas: a possible role for Tregs and T-cell exhaustion in reducing T-cell responses. J Invest Dermatol (2013) 1.06
Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients. J Transl Med (2012) 1.06
High-throughput identification of potential minor histocompatibility antigens by MHC tetramer-based screening: feasibility and limitations. PLoS One (2011) 1.03
High-throughput T-cell epitope discovery through MHC peptide exchange. Methods Mol Biol (2009) 1.00
Temporary regression of Merkel cell carcinoma metastases after cessation of cyclosporine. Transplantation (2002) 0.99
MHC-based detection of antigen-specific CD8+ T cell responses. Cancer Immunol Immunother (2010) 0.98
A flow cytometry-based assay to assess minute frequencies of CD8+ T cells by their cytolytic function. J Immunol Methods (2010) 0.89
Merkel cell carcinoma and Merkel cell polyomavirus: evidence for hit-and-run oncogenesis. J Invest Dermatol (2011) 0.88
T cell epitope mapping of JC polyoma virus-encoded proteome reveals reduced T cell responses in HLA-DRB1*04:01+ donors. J Virol (2013) 0.87
Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med (2012) 11.72
ATR regulates fragile site stability. Cell (2002) 4.74
Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features. J Am Acad Dermatol (2008) 4.69
Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet (2011) 3.91
MC polyomavirus is frequently present in Merkel cell carcinoma of European patients. J Invest Dermatol (2008) 3.29
Activation of the MAP kinase pathway induces apoptosis in the Merkel cell carcinoma cell line UISO. J Invest Dermatol (2007) 3.26
Rumi is a CAP10 domain glycosyltransferase that modifies Notch and is required for Notch signaling. Cell (2008) 3.09
Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov (2006) 3.08
Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J Carcinog (2004) 3.02
Sentinel lymph node biopsy for evaluation and treatment of patients with Merkel cell carcinoma: The Dana-Farber experience and meta-analysis of the literature. Arch Dermatol (2006) 2.92
Merkel cell polyomavirus-infected Merkel cell carcinoma cells require expression of viral T antigens. J Virol (2010) 2.88
Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system. J Am Acad Dermatol (2010) 2.83
Merkel cell polyomavirus is more frequently present in North American than Australian Merkel cell carcinoma tumors. J Invest Dermatol (2008) 2.80
Human Merkel cell polyomavirus infection II. MCV is a common human infection that can be detected by conformational capsid epitope immunoassays. Int J Cancer (2009) 2.77
Merkel cell carcinoma: more deaths but still no pathway to blame. J Invest Dermatol (2007) 2.72
Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers. Nat Methods (2009) 2.57
A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med (2002) 2.55
Transcriptome-wide studies of merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival. J Clin Oncol (2011) 2.52
Generation of peptide-MHC class I complexes through UV-mediated ligand exchange. Nat Protoc (2006) 2.47
Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol (2010) 2.33
Integration of growth factor and nutrient signaling: implications for cancer biology. Mol Cell (2003) 2.29
Activation of the ATR-mediated DNA damage response by the HIV-1 viral protein R. J Biol Chem (2003) 2.26
Association of Merkel cell polyomavirus-specific antibodies with Merkel cell carcinoma. J Natl Cancer Inst (2009) 2.22
Antibodies to merkel cell polyomavirus T antigen oncoproteins reflect tumor burden in merkel cell carcinoma patients. Cancer Res (2010) 2.14
Quantitation of human seroresponsiveness to Merkel cell polyomavirus. PLoS Pathog (2009) 2.08
Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators. Blood (2010) 2.01
ATR-Chk1 pathway inhibition promotes apoptosis after UV treatment in primary human keratinocytes: potential basis for the UV protective effects of caffeine. J Invest Dermatol (2009) 1.86
TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients. Oncoimmunology (2012) 1.78
Conditional MHC class I ligands and peptide exchange technology for the human MHC gene products HLA-A1, -A3, -A11, and -B7. Proc Natl Acad Sci U S A (2008) 1.77
Parallel detection of antigen-specific T cell responses by combinatorial encoding of MHC multimers. Nat Protoc (2012) 1.76
Radiation monotherapy as regional treatment for lymph node-positive Merkel cell carcinoma. Cancer (2010) 1.74
Human immunodeficiency virus type 1 Vpr-mediated G2 arrest requires Rad17 and Hus1 and induces nuclear BRCA1 and gamma-H2AX focus formation. Mol Cell Biol (2004) 1.66
B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis. PLoS One (2007) 1.65
Vitiligo and melanoma-associated hypopigmentation (MAH): shared and discriminative features. J Dtsch Dermatol Ges (2008) 1.61
Vascular E-selectin expression correlates with CD8 lymphocyte infiltration and improved outcome in Merkel cell carcinoma. J Invest Dermatol (2013) 1.58
Identification of novel survivin-derived CTL epitopes. Cancer Biol Ther (2004) 1.56
Role of matrix metalloproteinases in melanoma cell invasion. Biochimie (2005) 1.54
Dissection of T-cell antigen specificity in human melanoma. Cancer Res (2012) 1.52
A robust small-molecule microarray platform for screening cell lysates. Chem Biol (2006) 1.52
The universal character of the tumor-associated antigen survivin. Clin Cancer Res (2007) 1.50
An intact retinoblastoma protein-binding site in Merkel cell polyomavirus large T antigen is required for promoting growth of Merkel cell carcinoma cells. Int J Cancer (2011) 1.49
Anti-cancer therapies targeting the tumor stroma. Cancer Immunol Immunother (2007) 1.49
Cytotoxic T cells. J Invest Dermatol (2006) 1.47
Asymmetric lateral distribution of melanoma and Merkel cell carcinoma in the United States. J Am Acad Dermatol (2011) 1.47
Array-CGH reveals recurrent genomic changes in Merkel cell carcinoma including amplification of L-Myc. J Invest Dermatol (2008) 1.42
High-throughput identification of antigen-specific TCRs by TCR gene capture. Nat Med (2013) 1.40
The etiology and epidemiology of merkel cell carcinoma. Curr Probl Cancer (2010) 1.39
Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother (2008) 1.37
Merkel cell polyomavirus-specific CD8⁺ and CD4⁺ T-cell responses identified in Merkel cell carcinomas and blood. Clin Cancer Res (2011) 1.36
Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B. Clin Cancer Res (2009) 1.34
Modular nucleic acid assembled p/MHC microarrays for multiplexed sorting of antigen-specific T cells. J Am Chem Soc (2009) 1.34
Merkel cell carcinoma: recent insights and new treatment options. Curr Opin Oncol (2012) 1.30
Expression of stress-induced MHC class I related chain molecules on human melanoma. J Invest Dermatol (2002) 1.30
Systemic immune suppression predicts diminished Merkel cell carcinoma-specific survival independent of stage. J Invest Dermatol (2012) 1.30
Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. J Clin Oncol (2005) 1.27
Merkel cell carcinoma adjuvant therapy: current data support radiation but not chemotherapy. J Am Acad Dermatol (2007) 1.27
Immune-suppressive properties of the tumor microenvironment. Cancer Immunol Immunother (2013) 1.27
Macrophage migration inhibitory factor contributes to the immune escape of ovarian cancer by down-regulating NKG2D. J Immunol (2008) 1.23
Regulators of apoptosis: suitable targets for immune therapy of cancer. Nat Rev Drug Discov (2005) 1.22
Merkel polyomavirus-specific T cells fluctuate with merkel cell carcinoma burden and express therapeutically targetable PD-1 and Tim-3 exhaustion markers. Clin Cancer Res (2013) 1.22
Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells. Cancer Res (2009) 1.19
Identification of heme oxygenase-1-specific regulatory CD8+ T cells in cancer patients. J Clin Invest (2009) 1.19
Expression of matrix metalloproteinases in the microenvironment of spontaneous and experimental melanoma metastases reflects the requirements for tumor formation. Cancer Res (2003) 1.14
Merkel cell polyomavirus large T antigen has growth-promoting and inhibitory activities. J Virol (2013) 1.14
Chemical genetics: elucidating biological systems with small-molecule compounds. J Invest Dermatol (2007) 1.14
IGFBP7 is not required for B-RAF-induced melanocyte senescence. Cell (2010) 1.13
Immunogenicity of constitutively active V599EBRaf. Cancer Res (2004) 1.12
Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: a multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG). Melanoma Res (2003) 1.12
High-level expression of wild-type p53 in melanoma cells is frequently associated with inactivity in p53 reporter gene assays. PLoS One (2011) 1.11
Dermatofibrosarcoma protuberans. J Natl Compr Canc Netw (2012) 1.11
CD147 impacts angiogenesis and metastasis formation. Cancer Invest (2009) 1.11
Effect of caffeine on the ATR/Chk1 pathway in the epidermis of UVB-irradiated mice. Cancer Res (2008) 1.10
Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial. Cancer Immunol Immunother (2012) 1.08
The immune system strikes back: cellular immune responses against indoleamine 2,3-dioxygenase. PLoS One (2009) 1.07
A new American Joint Committee on Cancer staging system for cutaneous squamous cell carcinoma: creation and rationale for inclusion of tumor (T) characteristics. J Am Acad Dermatol (2011) 1.06
Tumor-specific T cells in human Merkel cell carcinomas: a possible role for Tregs and T-cell exhaustion in reducing T-cell responses. J Invest Dermatol (2013) 1.06
Merkel cell polyomavirus status is not associated with clinical course of Merkel cell carcinoma. J Invest Dermatol (2011) 1.06
Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients. J Transl Med (2012) 1.06
Successful treatment with Ipilimumab and Interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease. Cancer Immunol Immunother (2014) 1.06
Effector CD4 and CD8 T cells and their role in the tumor microenvironment. Cancer Microenviron (2012) 1.05
Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase. Clin Cancer Res (2013) 1.05